174 related articles for article (PubMed ID: 18333902)
1. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
[TBL] [Abstract][Full Text] [Related]
2. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
Soós N; Shakery K; Mrowietz U
Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer: new preparation. No place in multiple sclerosis.
Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
[TBL] [Abstract][Full Text] [Related]
5. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
Edgar CM; Brunet DG; Fenton P; McBride EV; Green P
Can J Neurol Sci; 2004 Feb; 31(1):58-63. PubMed ID: 15038472
[TBL] [Abstract][Full Text] [Related]
6. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
Johnson KP; Ford CC; Lisak RP; Wolinsky JS
Acta Neurol Scand; 2005 Jan; 111(1):42-7. PubMed ID: 15595937
[TBL] [Abstract][Full Text] [Related]
7. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.
Drago F; Brusati C; Mancardi G; Murialdo A; Rebora A
Arch Dermatol; 1999 Oct; 135(10):1277-8. PubMed ID: 10522686
[No Abstract] [Full Text] [Related]
8. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.
Hwang L; Orengo I
Cutis; 2001 Oct; 68(4):287-8. PubMed ID: 11710450
[No Abstract] [Full Text] [Related]
9. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
[TBL] [Abstract][Full Text] [Related]
10. Systemic reaction to glatiramer acetate.
Bayerl C; Bohland P; Jung EG
Contact Dermatitis; 2000 Jul; 43(1):62-3. PubMed ID: 10902605
[No Abstract] [Full Text] [Related]
11. Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case report.
Zecca C; Mainetti C; Blum R; Gobbi C
BMC Neurol; 2015 Dec; 15():249. PubMed ID: 26630967
[TBL] [Abstract][Full Text] [Related]
12. Localized lipoatrophy after prolonged treatment with copolymer 1.
Mancardi GL; Murialdo A; Drago F; Brusati C; Croce R; Inglese M; Ratto S
J Neurol; 2000 Mar; 247(3):220-1. PubMed ID: 10787120
[No Abstract] [Full Text] [Related]
13. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
Johnson KP; Brooks BR; Ford CC; Goodman AD; Lisak RP; Myers LW; Pruitt AA; Rizzo MA; Rose JW; Weiner LP; Wolinsky JS
Mult Scler; 2003 Dec; 9(6):585-91. PubMed ID: 14664471
[TBL] [Abstract][Full Text] [Related]
14. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group.
Liu C; Blumhardt LD
J Neurol Sci; 2000 Dec; 181(1-2):33-7. PubMed ID: 11099709
[TBL] [Abstract][Full Text] [Related]
15. [Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)].
Gaudez C; Regnier S; Aractingi S; Heinzlef O
Rev Neurol (Paris); 2003 May; 159(5 Pt 1):571-3. PubMed ID: 12773903
[TBL] [Abstract][Full Text] [Related]
16. Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate.
Nolden S; Casper C; Kuhn A; Petereit HF
Mult Scler; 2005 Apr; 11(2):245-8. PubMed ID: 15794402
[TBL] [Abstract][Full Text] [Related]
17. [New immunomodulator for multiple sclerosis patients. 30% fewer relapse rates].
MMW Fortschr Med; 2002 May; Suppl 2():88. PubMed ID: 12070870
[No Abstract] [Full Text] [Related]
18. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
Ziemssen T; Neuhaus O; Hohlfeld R
Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
[TBL] [Abstract][Full Text] [Related]
19. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
[TBL] [Abstract][Full Text] [Related]
20. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.
Fraser C; Hadjimichael O; Vollmer T
J Neurosci Nurs; 2001 Oct; 33(5):231-9. PubMed ID: 11668881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
